Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Revolution Medicines (RVMD) Shares Outstanding (Diluted Average): 2020-2025

Historic Shares Outstanding (Diluted Average) for Revolution Medicines (RVMD) over the last 5 years, with Sep 2025 value amounting to $189.2 million.

  • Revolution Medicines' Shares Outstanding (Diluted Average) rose 13.42% to $189.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $189.2 million, marking a year-over-year increase of 13.42%. This contributed to the annual value of $167.7 million for FY2024, which is 48.24% up from last year.
  • As of Q3 2025, Revolution Medicines' Shares Outstanding (Diluted Average) stood at $189.2 million, which was up 0.34% from $188.6 million recorded in Q2 2025.
  • Over the past 5 years, Revolution Medicines' Shares Outstanding (Diluted Average) peaked at $189.2 million during Q3 2025, and registered a low of $72.8 million during Q4 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $165.1 million (2024), whereas its average is $150.4 million.
  • Data for Revolution Medicines' Shares Outstanding (Diluted Average) shows a peak YoY soared of 73.71% (in 2024) over the last 5 years.
  • Revolution Medicines' Shares Outstanding (Diluted Average) (Quarterly) stood at $72.8 million in 2021, then grew by 10.74% to $80.6 million in 2022, then surged by 40.34% to $113.1 million in 2023, then spiked by 48.24% to $167.7 million in 2024, then grew by 13.42% to $189.2 million in 2025.
  • Its last three reported values are $189.2 million in Q3 2025, $188.6 million for Q2 2025, and $188.1 million during Q1 2025.